Repligen Corporation $RGEN Stock Position Raised by Congress Asset Management Co.

Congress Asset Management Co. grew its position in shares of Repligen Corporation (NASDAQ:RGEN) by 241.4% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 746,306 shares of the biotechnology company’s stock after buying an additional 527,714 shares during the quarter. Congress Asset Management Co. owned approximately 1.33% of Repligen worth $122,290,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also made changes to their positions in RGEN. Measured Wealth Private Client Group LLC acquired a new position in Repligen in the third quarter worth approximately $29,000. CWM LLC grew its position in Repligen by 67.2% in the third quarter. CWM LLC now owns 336 shares of the biotechnology company’s stock worth $45,000 after acquiring an additional 135 shares in the last quarter. Johnson Financial Group Inc. acquired a new position in shares of Repligen during the 3rd quarter worth $65,000. Trust Co. of Vermont acquired a new position in shares of Repligen during the 3rd quarter worth $67,000. Finally, Wilmington Savings Fund Society FSB raised its holdings in shares of Repligen by 2,750.0% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 513 shares of the biotechnology company’s stock valued at $69,000 after purchasing an additional 495 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

RGEN has been the subject of several analyst reports. Barclays reduced their price objective on shares of Repligen from $200.00 to $175.00 and set an “overweight” rating for the company in a research note on Wednesday, February 25th. KeyCorp restated an “overweight” rating on shares of Repligen in a report on Wednesday, February 25th. Weiss Ratings downgraded Repligen from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Tuesday, March 3rd. Wells Fargo & Company lowered their price objective on Repligen from $190.00 to $180.00 and set an “overweight” rating on the stock in a report on Wednesday, February 25th. Finally, HC Wainwright raised their price objective on Repligen from $180.00 to $208.00 and gave the company a “buy” rating in a research note on Monday. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Repligen has an average rating of “Moderate Buy” and a consensus price target of $176.92.

Repligen Stock Up 2.2%

Repligen stock opened at $116.35 on Tuesday. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.37 and a quick ratio of 7.12. Repligen Corporation has a fifty-two week low of $102.96 and a fifty-two week high of $175.77. The firm has a fifty day moving average price of $139.18 and a two-hundred day moving average price of $146.88. The firm has a market cap of $6.55 billion, a price-to-earnings ratio of 136.88, a P/E/G ratio of 2.23 and a beta of 1.15.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings results on Tuesday, February 24th. The biotechnology company reported $0.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.44 by $0.05. Repligen had a return on equity of 4.71% and a net margin of 6.62%.The company had revenue of $197.91 million for the quarter, compared to the consensus estimate of $192.23 million. During the same period last year, the business posted $0.44 earnings per share. The firm’s revenue was up 18.1% compared to the same quarter last year. Repligen has set its FY 2026 guidance at 1.930-2.010 EPS. As a group, analysts forecast that Repligen Corporation will post 1.72 earnings per share for the current year.

Repligen Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.